Skip to main content
. 2020 Aug 20;21(17):6001. doi: 10.3390/ijms21176001

Figure 6.

Figure 6

Graphical representation of standard treatments and new prospects for RA. Non-biological agents, synthetic disease-modifying anti-rheumatic drugs (sDMARDs), and biological disease-modifying anti-rheumatic drugs (bDMARDs) are among the main standard treatments for RA patients. Using inhibitors of multinucleation and modulators of macrophages (M) polarisation could offer alternative novel strategies in RA.